Liquid Biopsy Market Overview:
The global liquid biopsy market size was valued at USD 7.05 billion in 2022 and is expected to grow at a CAGR of 14.4% during the forecast period.
A blood test called a liquid biopsy determines whether the patient's blood contains circulating tumor DNA (ctDNA). Target setting, drug resistance, tumor heterogeneity, early detection screening, and liquid biopsy are just a few of the many applications that liquid biopsy has in the diagnosis and treatment of cancer. Analysis and sampling of biological tissue that is not solid, particularly blood, is known as a liquid biopsy or fluid phase biopsy. The advantages of liquid biopsy include non-invasiveness, accuracy, speed, and especially real-time results. In the future, it might take the place of tissue biopsy and be able to overcome the heterogeneity of malignancies. It has been demonstrated that genetic material from tumors can be found in a number of bodily fluids, including blood, urine, stool, saliva, and cerebrospinal fluid (CSF). Liquid biopsies serve a number of purposes.
Request Sample Report of Liquid Biopsy Market @ https://wemarketresearch.com/sample-request/liquid-biopsy-market/607
Market Dynamics:
Drivers:
The rising incidence of cancer: Radiologists are essential to cancer care because they use imaging for diagnosis, treatment planning, screening, and follow-up. Furthermore, image-guided tissue samples performed by radiologists enable more precise diagnosis and molecular characterization of tumor cells. Because nuclear medicine doctors provide radionuclide treatment and interventional radiologists provide minimally invasive local-regional treatments, radiologists are involved in cancer therapy. Blood collection from a peripheral venous location, such as the median cubital vein, is often impacted by liquid biopsy. Liquid biopsy has become more popular in the cancer field because of its ability to detect specific genetic alterations non-invasively and in tandem with targeted therapy. Atherosclerosis and a heart attack have been diagnosed in non-cancerous liquid biopsies.
Restraints:
The reduced sensitivity of some liquid biopsies: Normal DNA is mostly present in the liquid biopsy samples. Compared to hematological molecules in a blood sample, circulating tumor DNA is uncommon, which poses a hurdle to liquid biopsy's clinical sensitivity. Another obstacle facing small businesses is a shortage of qualified staff to oversee the systems.
Opportunities:
Benefits of liquid biopsy technology: The market is expected to develop because tissue sections needed for traditional biopsy techniques are currently unavailable. In addition, the market is expanding due to the increasing number of current clinical trials for creating novel solutions. Additionally, a number of advantages linked to liquid biopsies, such as increased accuracy, reduced invasiveness, and post-treatment monitoring, fuel industry expansion.
Challenges:
Lack of clinical utility: The expansion of the liquid biopsy market is hampered by the absence of extensive clinical trials proving the procedure's therapeutic value.
Liquid Biopsy Market – Segmentation
Liquid Biopsy Market on the basis of Sampling type, the market is fragmented into:
- Blood Sampling Liquid Biopsy
- Urine Sampling Liquid Biopsy and Saliva
- Other Tissue Fluids Sampling Liquid Biopsy
Liquid Biopsy Market on the basis of Products and services, the market is bifurcated into:
- Assays Kits
- Instruments and Services
Liquid Biopsy Market on the basis of circulating biomarker, the market is classified into:
- Circulating Tumour Cells
- Circulating Tumour DNA (CTDNA)
- Cell-Free DNA
- Extracellular Vesicles (EVS)
- Other Circulating Biomarkers
Liquid Biopsy Market on the basis of clinical application, the market is categorized into:
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
Liquid Biopsy Market on the basis of end user, the market is segregated into:
- Reference Laboratories
- Hospitals and Physician Laboratories
- Academic and Research Centres
- Other End Users
Liquid Biopsy Market –Regional Analysis
The solid system of healthcare facilities, growing investment from major players in the development of advanced devices, an increasing number of processes for drug development, the strict regulatory environment in the pharmaceutical industry, and the increasing number of research activities in this region all contribute to North America's dominance of the liquid biopsy market. Due to the rise in policy measures to raise awareness, an increase in medical tourism, expanding research activities in the region, an increase in cancer cases, and an increase in the demand for high-quality healthcare in the region, Asia-Pacific is predicted to experience significant growth during the forecast period.
Get a Purchase of This Report @ https://wemarketresearch.com/purchase/liquid-biopsy-market/607?license=single
Key Players in the Liquid Biopsy Market
Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific, Inc. (US), Guardant Health, Inc. (US), MDxHealth SA (Belgium), Exact Sciences Corporation (US), Illumina Inc. (US), Sysmex Inostics (US), Bio-Rad Laboratories, Inc. (US), Biocept, Inc. (US), NeoGenomics, Inc. (US), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences, Inc. (US), Exosome Diagnostics, Inc. (US), Agena Bioscience, Inc. (US), MedGenome Inc. (US), Epigenomics AG (Germany), and Personal Genome Diagnostics, Inc. (US)
About We Market Research:
WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
Contact Us:
Mr. Robbin Joseph
Corporate Sales, USA
We Market Research
USA: +1-724-618-3925
Websites: https://wemarketresearch.com/
Email: [email protected]
